This article presents an overview of endophthalmitis, a severe intraocular inflammatory condition that can develop following surgery, intravitreal injections (IVIs), or ocular trauma. Endogenous cases may also arise, particularly in patients with compromised immune systems. A broad spectrum of pathogens, including bacteria, fungi, and viruses, can be involved, with some displaying high virulence. Given the rapid progression and potential for vision-threatening complications or systemic involvement such as sepsis, immediate and appropriate intervention is essential. Surgical management, especially vitrectomy, plays a central role in treatment. The Complete Early Vitrectomy for Endophthalmitis (CEVE) protocol has demonstrated high effectiveness, particularly when integrated into outpatient ophthalmic surgical practices. This review describes the protocol's practical application in such settings. In addition, it discusses preventive strategies for ocular surgery and injections, with a particular focus on the judicious use of antimicrobial agents. Incorrect antibiotic use, including unnecessary prescribing, inadequate dosing, or prolonged treatment, remains a leading contributor to the development of antimicrobial resistance and warrants critical evaluation. In summary, the CEVE approach appears to offer broad efficacy across different causes of endophthalmitis. Povidone-iodine (PI) remains the most effective agent for perioperative antisepsis. The use of prophylactic antibiotics should be confined to brief, high-potency topical therapy following intraocular procedures, including cataract surgery and phacovitrectomy. Current evidence does not support the routine use of prophylactic antibiotics after intravitreal injections due to minimal benefit and the risk of promoting resistant organisms.
Intravitreal anti-vascular endothelial growth factor injections are widely used for retinal disorders but may occasionally lead to sterile endophthalmitis, a condition that can be challenging to distinguish from infectious endophthalmitis. We describe a series of five patients who developed acute intraocular inflammation within 24-48 hours of receiving bevacizumab injections. These patients presented with decreased visual acuity and vitreous haze but reported minimal or no pain. All patients were managed urgently with pars plana vitrectomy according to the complete and early vitrectomy for endophthalmitis (CEVE) protocol, which included intraoperative antibiotic infusion and microbiological sampling. Cultures from the vitreous samples and the bevacizumab vial were negative. Following early vitrectomy, inflammation resolved in all patients, and visual acuity returned to baseline within 30 days. No postoperative complications were observed. None of the 38 additional patients who received injections from the same vial developed endophthalmitis. These findings support an immune-mediated, noninfectious mechanism for these cases and suggest that early vitrectomy within the CEVE framework promotes rapid resolution and favorable visual recovery. Continued vigilance and further research are warranted to refine management strategies for sterile endophthalmitis.
Faricimab (Vabysmo, Roche, EU) may improve treatment durability while maintaining functional and anatomical outcomes in neovascular age-related macular degeneration (nAMD). This single-centre retrospective study evaluated 52 eyes of 49 refractory nAMD patients switched from ranibizumab, aflibercept 2 mg, or brolucizumab to faricimab. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), injection intervals, optical coherent tomography (OCT) fluid, and adverse events were assessed at baseline and last follow-up. Mean age was 78.8 years. Before switching, patients had received a mean of 21.85 injections over 996 days, and 77.4% were short responders, with a mean treatment interval of 6.3 weeks. After a mean 466 days of faricimab treatment, BCVA remained stable, changing from 0.389 to 0.378 logMAR (mean change −0.012 logMAR; p = 0.509). BCVA improved in 19.2%, remained stable in 67.3%, and worsened in 13.5% of eyes. CRT decreased significantly from 257.8 to 224.8 μm (mean change −32.9 μm; p = 0.00005). The mean injection interval increased to 8.0 weeks, reaching 8.42 weeks among eyes continuing faricimab. Thirteen eyes (25%) required switching to aflibercept 8 mg because of recurrent fluid or OCT worsening. No endophthalmitis or severe intraocular inflammation occurred. Faricimab maintained vision, improved macular anatomy, and reduced treatment burden, although some refractory eyes required further treatment escalation.
Purpose: To present the clinical outcomes of a combined pharmacological and gas-assisted treatment approach for sub-macular haemorrhage secondary to neovascular age-related macular degeneration (nAMD). Methods: A retrospective analysis was conducted on ten patients with sub-macular haemorrhage secondary to nAMD treated between 2024 and 2025. Each patient received a single intravitreal injection of tissue plasminogen activator (tPA; alteplase, Actylise 10, Boehringer Ingelheim, Int.) and perfluoropropane (C₃F₈, Micromed) gas. This treatment was administered within 3 weeks of symptom onset (range 7-60 days). Subsequently, all patients received anti-VEGF injections of aflibercept (Eylea 2mg, or Eylea 8 mg, Bayer) using a treat-and-extend (T&Ex) regimen, started 7–14 days after the tPA + gas injection. Clinical evaluation included best-corrected visual acuity (BCVA), fundus photography, optical coherence tomography (OCT), and OCT- angiography angio-OCT at baseline and at 7 -14 days, 1 month, 3 months, and 6 months after the initial tPA + gas injection. Results: All patients showed rapid anatomical improvement of the haemorrhage. Visual acuity improved in the majority of cases, with an average gain of three ETDRS lines at four weeks, an additional three lines at three months, and over four lines at six months. No major adverse events were reported. One patient developed a transient intraocular-pressure rise, which was easily controlled with medication. Conclusion: Prompt combined therapy using intravitreal alteplase with C₃F₈ gas, followed by anti-VEGF treatment, may offer a safe and minimally invasive alternative to surgery for sub-macular haemorrhage due to nAMD, providing promising visual and anatomical outcomes.
Purpose: We aimed to present the clinical outcomes of a combined pharmacological and gas-assisted treatment for sub-macular haemorrhage secondary to neovascular age-related macular degeneration (nAMD). Methods: This retrospective case series included ten eyes with sub-macular haemorrhage (SMH) treated between January 2024 and September 2025. All patients received intravitreal alteplase (100 µg) and C3F8 gas, followed by aflibercept (2 mg or 8 mg) within a treat-and-extend regimen. BCVA- and OCT-based anatomical changes were recorded at baseline, 7–14 days, 1 month, 3 months, and 6 months. BCVA changes were analysed using repeated-measures testing. Results: Mean BCVA improved from 0.99 ± 0.21 logMAR at baseline to 0.89 ± 0.20 at 7–14 days, 0.80 ± 0.20 at 1 month, 0.60 ± 0.18 at 3 months, and 0.53 ± 0.20 at 6 months (p < 0.05 for overall change). Eight eyes (80 percent) showed restoration of foveal contour, while two developed foveal atrophy. No major adverse events occurred. Conclusion: Combined intravitreal alteplase and C3F8, followed by aflibercept, may provide favourable short-term visual and anatomical improvement in SMH secondary to nAMD. Early intervention appears beneficial, but larger controlled studies are needed to confirm these findings.
The review summarizes the management of endophthalmitis – and inflammatory reaction in the eye, which may occur postoperatively, after injections or following open-globe injury. It may also occur as an endogenous process in immunologically compromised patients. Causative organisms include bacteria, fungi, or viruses, some of which can be highly virulent. It is an acute and urgent ocular pathology with the potential for imminent loss of sight and/or the eyeball. Sepsis may also be a real threat. This is why it is of utmost importance to introduce quick and optimal management, with surgical treatment being the primary approach. Complete and Early Vitrectomy for Endophthalmitis (CEVE protocol) seems to be the best solution. The protocol for a One-Day Surgery Clinic set-up is described. We summarise preventive measures for ocular surgeries and intravitreal injections. The use and dosing of antibiotics for endophthalmitis and prophylaxis are also discussed. One should be aware that due to the increasing microbial resistance to antibiotics, their overuse, prolonged usage, or unnecessary treatment may deprive us of an effective defense against bacteria. In conclusion CEVE strategy is the most effective treatment for endophthalmitis, irrespective of the cause. Povidone iodine in perioperative management is the best solution for endophthalmitis prevention regardless of the cause. The use of antibiotics in the prevention of endophthalmitis should be limited to a short postoperative period when prescribed in drops. However, it is strongly recommended following eye surgery, especially after cataract extraction, phacovitrectomy, or MIGS procedures involving cataract removal. Even though it is still controversial, we recommend against prescribing antibiotics after intra-vitreal injections to prevent the promotion of bacterial resistance.